AU2003244511A1 - Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage - Google Patents

Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage

Info

Publication number
AU2003244511A1
AU2003244511A1 AU2003244511A AU2003244511A AU2003244511A1 AU 2003244511 A1 AU2003244511 A1 AU 2003244511A1 AU 2003244511 A AU2003244511 A AU 2003244511A AU 2003244511 A AU2003244511 A AU 2003244511A AU 2003244511 A1 AU2003244511 A1 AU 2003244511A1
Authority
AU
Australia
Prior art keywords
mgf
insulin
prevention
growth factor
splice variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003244511A
Other languages
English (en)
Inventor
Geoffrey Goldspink
Paul Goldspink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
University of Illinois System
Original Assignee
University College London
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London, University of Illinois at Urbana Champaign, University of Illinois System filed Critical University College London
Publication of AU2003244511A1 publication Critical patent/AU2003244511A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003244511A 2002-02-07 2003-02-06 Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage Abandoned AU2003244511A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0202906.4 2002-02-07
GBGB0202906.4A GB0202906D0 (en) 2002-02-07 2002-02-07 Prevention of myocardial damage
PCT/GB2003/000537 WO2003066082A1 (en) 2002-02-07 2003-02-06 Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage

Publications (1)

Publication Number Publication Date
AU2003244511A1 true AU2003244511A1 (en) 2003-09-02

Family

ID=9930632

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003244511A Abandoned AU2003244511A1 (en) 2002-02-07 2003-02-06 Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage

Country Status (9)

Country Link
US (4) US20050048028A1 (https=)
EP (1) EP1480669B1 (https=)
JP (1) JP2005516997A (https=)
AU (1) AU2003244511A1 (https=)
DK (1) DK1480669T3 (https=)
ES (1) ES2432082T3 (https=)
GB (1) GB0202906D0 (https=)
PT (1) PT1480669E (https=)
WO (1) WO2003066082A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
AU2006224334A1 (en) * 2005-03-18 2006-09-21 The Board Of Trustees Of The University Of Illinois Mecano growth factor peptides and their use
WO2006097682A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use
KR101459789B1 (ko) 2006-06-09 2014-11-07 노파르티스 아게 안정화된 인슐린-유사 성장 인자 폴리펩티드
WO2009012443A1 (en) * 2007-07-18 2009-01-22 The Board Of Trustees Of The University Of Illinois Nanoparticles for the elution of growth factors for recovery and regeneration of organs
CN101891812B (zh) * 2010-07-09 2012-10-17 山西大学 力生长因子多肽及其制备方法和用途
CN103031277B (zh) * 2011-09-29 2015-07-15 重庆大学 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460147C2 (de) 1974-12-19 1983-05-05 Ibm Deutschland Gmbh, 7000 Stuttgart Anordnung zur Dekomprimierung komprimierter Information für aus schwarzen und weißen Bereichen zusammengesetze darzustellende Zeichen
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4963665A (en) 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DK0437563T3 (da) 1989-08-07 1995-05-29 Debio Rech Pharma Sa Bioligiske aktive lægemiddelpolymerderivater
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
SE9101341D0 (sv) 1991-05-03 1991-05-03 Kabi Pharmacia Ab New medicinal use
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
EP0597033B1 (en) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
EP0615452A4 (en) 1991-11-25 1995-07-12 Inst Molecular Biology Inc MEDICINE SERVING THE PROMOTION OF THE GROWTH OF A NERVE IN MAMMALS.
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
AU1178395A (en) 1993-11-12 1995-05-29 North Shore University Hospital Research Corporation Method of treating muscular dystrophy
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650496A (en) * 1995-04-14 1997-07-22 Cephalon, Inc. IGF-I purification process
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
DE69939036D1 (de) 1998-04-28 2008-08-14 Serono Lab PEG Konjugate von LHRH Analogen
GB9926968D0 (en) 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) * 2000-05-10 2000-06-28 Univ London Repair of nerve damage
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
GB0203552D0 (en) 2002-02-14 2002-04-03 Beaumont Nicholas J Peptide growth factor
WO2006097682A1 (en) 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use

Also Published As

Publication number Publication date
DK1480669T3 (da) 2013-05-06
WO2003066082A1 (en) 2003-08-14
US20080039390A1 (en) 2008-02-14
US20130210723A1 (en) 2013-08-15
US20050048028A1 (en) 2005-03-03
JP2005516997A (ja) 2005-06-09
ES2432082T3 (es) 2013-11-29
GB0202906D0 (en) 2002-03-27
PT1480669E (pt) 2013-05-22
US9919031B2 (en) 2018-03-20
US20180271942A1 (en) 2018-09-27
EP1480669A1 (en) 2004-12-01
EP1480669B1 (en) 2013-01-23

Similar Documents

Publication Publication Date Title
AU2003210109A1 (en) Protective layers for optical coatings
AU2003248651A1 (en) Optical metrology of single features
AU2003261302A1 (en) Storage management bridges
AU2003255482A1 (en) Use of 4 amino-quinazolines as anti cancer agents
AU2003226015A1 (en) Pool cleaner
AU2003250690A1 (en) Auto-characterization of optical devices
AU7115700A (en) Optical performance monitor
AU2003272519A1 (en) Microscope with extended field of vision
AU2003227682A1 (en) Protective coating composition
AU2002257671A1 (en) Optical structure for multi-photon excitation and the use thereof
AU2003216296A1 (en) Reducing the susceptibility of titanium nitride optical layers to crack
AU2003259438A1 (en) Di and trifluoro-triazolo-pyridines anti-inflammatory compounds
AU2003220968A1 (en) Anti-inflammatory agent
AU2003208608A1 (en) Antifouling detergent for hard surfaces
AU2003235786A1 (en) Lenses having chromatic effect
AU2003208609A1 (en) Antifouling detergent for hard surfaces
AU2003258662A1 (en) Use of 4-amino-quinazolines as anti cancer agents
AU2003263502A1 (en) Storage
AU2003244511A1 (en) Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage
AU2003278909A1 (en) The use of benzisoselenazolone compounds against ischemic myocardial damage
AU2003282510A1 (en) Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
AU2003254902A1 (en) Myocardial cell protecting agents
AU2003212403A1 (en) Interferometer
AU2003232189A1 (en) Antifouling agent
AU2002368548A1 (en) Novel branched alpha-cyanostilbene fluorophores

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase